Sterling T. Wall

Sterling Wall graduated from Tufts University with his BS in Chemical and Biological Engineering. He joined BioVex (later Amgen) in a purification process development role and contributed significantly to the process characterization and commercialization of Imlygic®, a novel and first-in-class oncolytic viral therapy. In 2015, Sterling joined bluebird bio to build its lentiviral vector process characterization and commercialization capabilities for late-stage autologous gene therapy products. Sterling is currently a team leader in vector purification process development, working on several gene therapy and immunotherapy assets in development for EU and US markets.